



HCC-UK Programme

THURSDAY 19TH MARCH 2026

11:55-12:00	Welcome and Introduction Chair: Matthew Hoare	
12:00-12:15	Elucidating the role of mitochondrial nucleotide metabolism in hepatocellular carcinoma Speaker: Sarah Gohar, CRUK Scotland Institute	
12:15-12:30	Developing a preclinical mouse model to study image-guided stereotactic ablative radiotherapy and systemic treatment Speaker: Stephanie May, CRUK Scotland Institute	
12:30-13:00	Genetic background sets the trajectory of liver cancer evolution Speaker: Dr Sarah Aitken, Yale School of Medicine (Virtual)	
13:00-14.00	Lunch – Posters & Exhibition	
Session 2- Microenvironment in HCC Chair: Shish Shetty		
14.00-14.30	Roles of hepatic metabolism in anti-tumour-immunity Speaker: Prof Dimitrios Anastasiou, Francis Crick Institute	
14:30-14:45	Liver-specific microbiota and microbial-derived metabolites rewire metabolic and structural phenotypes in hepatocellular carcinoma (HCC) Speaker: Niyati Raj, Roger Williams Institute of Liver Studies	
14:45-15.00	Spatial-temporal analysis of human-correlated mouse models reveals steatosis-linked evolutionary heterogeneity of hepatocellular carcinoma Speaker: Fiona Chalmers, CRUK Scotland Institute	
15:00-15:30	Tissue-resident memory CD8 T cells: master deciphers of their environment" Speaker: Dr Laura Pallett, University College London	
15:30-16.00	Refreshments & Exhibition	

Session 3 - Microenvironment in HCC

Chair: **Tom Bird**



16:00–16:30	From Vector Design to Scalable Manufacturing: Optimization of Cytokine-Armored GPC3 CAR-NK Cells for Enhanced Anti-HCC Activity Speaker: Dr Ester Badami, RiMED Foundation, Palermo	
16:30–16:45	Spatial multi-omic profiling reveals metal-metabolic microenvironments that program regulatory T cell function in hepatocellular carcinoma Speaker: Leonard Bellersheim, King's College London	
16:45-17:00	Highly cytotoxic gamma delta T cells combined with locoregional drug delivery demonstrates effective treatment for hepatocellular carcinoma Speaker: Nekisa Zakeri, University Of Birmingham	
17:00-17:30	Un-hijacking the immune system to improve response to IO in HCC Speaker: Prof Tom Marron, Mount Sinai School of Medicine, NY (Virtual)	
19.30-11.00	HCC-UK Dinner	

State of the Art HCC management in 2026

FRIDAY 20TH MARCH 2026

Session 1 - Surgical treatment

Chair: Stephanos Pericleous and David Wallace

08:15	<i>Registration</i>	
08.30 -09.00	AstraZeneca Sponsored Symposium	
09:00-09:10	Welcome <i>Speaker:</i> Abid Suddle	
09:10-09:35	Liver Resection in 2026....in whom, and how Speaker: Mr Charles Imber	
09.35-10.10	Debate: Criteria for Liver Transplant should be extended in the era of LDLT Pro – Shahid Farid Con – Rohit Gaurav	
10:10-10:40	Best of Abstracts – Chair – Dr Nekisa Zakeri	



	<p>Selective Internal Radiation Therapy (SIRT) – a UK Multicentre Audit on Treatment Practice Speaker: David Barnes, New castle University</p> <p>Combining locoregional therapies with immune checkpoint inhibitors may improve outcomes for patients with advanced hepatocellular carcinoma Speaker: Mzamo Mbelle, Kings College Hospital</p>	
10.40-11:10	<i>Refreshments and Exhibition</i>	
Session 2: Joint session with BSIR IO Chairs: Dr David Bowden and Dr Praveen Peddu		
11:10 -11.30	<p>SABR in 2026 Speaker: Dr James Good</p>	
11.30-11.50	<p>SIRT in 2026 Speaker: Dr Peter Littler</p>	
11.50-12.10	<p>IA embolic therapy in 2026 Speaker: Prof Mark Calloway</p>	
12.10-12.30	<p>Histotripsy: New fad or here to stay? Speaker – Prof Tim Ziemelewicz</p>	
12.30-13.00	<p>Best of Abstracts – Chair – Prof Shish Shetty</p> <p><i>The urinary steroid metabolome can distinguish between cirrhosis and HCC and between certain aetiologies of cirrhosis.</i> Speaker: Hamish Miller, OCDEM, University of Oxford</p> <p>Use of Stereotactic Ablative Radiotherapy as a Locoregional Treatment Option for Hepatocellular Carcinoma – Outcomes at a Regional Centre Speaker: Bosire Oroko, Royal Free Hospital</p>	
13.00-14.15	<i>Lunch – Poster viewing</i>	
13.15-13.45	Sponsor symposium	
Session 3 – Oncology Chairs: Alexa Childs & colleague from Bristol		
14.15-14.35	<p>Outline of Systemic therapy for advanced stage HCC in 2026 Speaker: Dr Mabel Teng</p>	



14.35-14.55	Adjuvant and neo-adjuvant Systemic therapy Speaker: Dr Antonio D'Allesio	
14.55-15.15	Combination of systemic therapy and loco-regional therapy Speaker: Prof Jeff Evans	
15.20-15.45	<i>Refreshments and Exhibition</i>	
Session 4: MDT Host: Dr Abid Suddle		
15.45-16.45	Hepatologist - Prof Shahid Khan Surgeon – David Wallace Pathologist - Dr Elizabeth Hepburn Radiologist on Panel - Dr David Bowden IR Radiologist - Prof Mark Calloway Oncologist - Dr Alexa Childs CNS: Alison Pritchard	
16.45-17.00	Wrap up and close	

Thank you to our Partners and Sponsors

Pharmaceutical companies have solely provided financial sponsorship, with no input into the arrangements or agenda of the meeting



GOLD Sponsor



SILVER Sponsor



EXHIBITION SPONSORS

